8-K/A: CDT Equity Files Amendment with Sarborg Financials

CDT Equity Inc. files an amendment to its Form 8-K to include financial statements and pro forma information related to its investment in Sarborg Limited.

Summary

• This filing is an amendment (No. 2) to a previous Form 8-K report by CDT Equity Inc. concerning its investment in Sarborg Limited.
• The amendment is being filed to include the required financial statements of Sarborg Limited (acquired business) and unaudited pro forma consolidated financial information.
• The financial statements of Sarborg Limited for the fiscal years ended December 31, 2025 and 2024, and for the six months ended June 30, 2026, are included.
• Unaudited pro forma consolidated financial statements giving effect to the Sarborg investment are also provided.
• The company previously reported an investment in Sarborg on February 19, 2026, and a subsequent investment on July 30, 2026, bringing its total ownership to approximately 24.76%.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as slightly negative due to the continued net losses and going concern disclosures, despite the strategic investment in Sarborg Limited.

Positives

• CDT Equity Inc. is expanding its stake in Sarborg Limited, a company focused on agentic intelligence and AI platforms.
• The inclusion of Sarborg's financial statements and pro forma information provides greater transparency regarding the acquired business.
• The pro forma statements offer a combined view of CDT Equity and Sarborg's financial position and operational results, aiding in understanding the potential impact of the investment.

Negatives

• Sarborg Limited has consistently generated operating losses since its inception and had an accumulated deficit of $0.8 million as of December 31, 2025, and $1.3 million as of June 30, 2026.
• Sarborg Limited had minimal cash and cash equivalents ($10,000 as of Dec 31, 2025, and $14,000 as of June 30, 2026), raising going concern doubts.
• Sarborg's net losses were $0.5 million for the year ended Dec 31, 2025, and $0.5 million for the six months ended June 30, 2026.
• The pro forma statements show a combined net loss for CDT Equity Inc. of $8.7 million for the six months ended June 30, 2026, and $39.4 million for the year ended December 31, 2025.

Risks

• Sarborg Limited faces risks common to development-stage companies in the life sciences and AI industries, including uncertainties in pre-clinical/clinical outcomes, regulatory approvals, and intellectual property protection.
• There is uncertainty regarding when Sarborg will realize significant revenue from commercialization.
• The pro forma financial information is presented for illustrative purposes and is not indicative of future results or financial position.
• The pro forma adjustments are based on available information and assumptions that management believes are reasonable, but actual results could differ.

Future Outlook

The pro forma financial information is presented for illustrative purposes and is not intended to represent or be indicative of the Company's consolidated results of operations or financial position that would have been reported had the investment and related transactions been completed as of the dates presented. Management expects Sarborg to continue generating operating losses and negative operating cash flows, requiring additional funding.

Management Comments

• Management believes its plans for debt and equity financings, along with a founder's guarantee, are probable of alleviating going concern doubts for Sarborg Limited.
• Management believes the pro forma adjustments are based on available information and reasonable assumptions, though actual results may differ.

Industry Context

StockSavvy.ai notes that this filing reflects CDT Equity's ongoing strategy to integrate AI capabilities through its investment in Sarborg Limited, aligning with broader industry trends in AI-driven drug discovery and development.

Comparison to Industry Standards

• No direct industry standard comparisons are provided within the filing for Sarborg's financial performance or the pro forma combined entity.
• The filing does not offer benchmarks against specific competitors or industry averages for revenue growth, profitability, or R&D investment relative to revenue.

Related Party Transactions

• All of Sarborg Limited's revenues during the periods presented were from contracts with CDT Equity (CDT), a related party.
• CDT Equity's CEO, Andrew Regan, is a member of Sarborg's board of directors.
• Mark Taylor, Sarborg's Founder and Director, is the sole director of Prospect Capital Management Limited and Prospect Finance Limited.
• CDT Equity acquired a 20% stake in Sarborg from Sarborg's investors on February 19, 2026, and an additional 4.76% on July 30, 2026.
• Manoira Corporation, from which Sarborg acquired patents, has a director who is also a director of Sarborg.
• Corvus Capital Limited, an investor in Sarborg, has a principal owner who is also a director of Sarborg.

Stakeholder Impact

• Shareholders of CDT Equity Inc. may see dilution from the issuance of pre-funded warrants as consideration for the Sarborg investment.
• The continued losses and going concern issues at Sarborg may impact investor confidence in CDT Equity's strategic investments.
• The integration of Sarborg's AI technology could potentially enhance CDT Equity's drug development capabilities, benefiting future stakeholders if successful.

Next Steps

• Sarborg Limited will continue to develop its AI platforms and decision-support tools.
• CDT Equity Inc. will continue to integrate Sarborg's capabilities into its pharmaceutical development and digital asset treasury management strategies.
• Further funding rounds are anticipated for Sarborg to support its business plan.

Key Dates

Recommendation

The filing indicates a strategic expansion into AI with Sarborg Limited, which is positive. However, Sarborg's ongoing losses, minimal cash, and going concern issues, coupled with the significant pro forma net losses for CDT Equity, present considerable risks. The investment is speculative, and while it aligns with industry trends, the financial performance does not yet justify a buy recommendation. A hold position allows for monitoring of Sarborg's progress and CDT Equity's ability to manage these investments effectively.

Keywords

Sarborg Limited, CDT Equity Inc., Financial Statements, Pro Forma, Acquisition, AI, Agentic Intelligence, Amendment